U.S. Household Products Stock News

NYSE:TGT
NYSE:TGTConsumer Retailing

Target Revamps Influencer Programs As Investors Weigh Social Commerce Impact

Target is overhauling its creator and influencer partnerships, winding down its existing affiliate program. The company is introducing two new platforms, Target Ambassadors for larger influencers and Club Target for smaller creators. This shift aims to reshape how Target uses social media for engagement, shopping, and brand loyalty. For investors tracking NYSE:TGT, this move comes as the stock trades at $130.19, with a return of 29.5% year to date and 42.6% over the past year. Those figures...
NasdaqGS:CIFR
NasdaqGS:CIFRSoftware

Cipher Digital Leans Into AI Data Centers As Bitcoin Exit Accelerates

Cipher Digital (NasdaqGS:CIFR) signed its third long term AI and high performance computing data center campus lease with an investment grade hyperscale tenant. The company completed a $2b high yield bond offering and closed a $200m revolving credit facility to fund its Black Pearl project and support further expansion. Cipher Digital has started winding down its Bitcoin mining operations, targeting a full exit and asset repurposing for HPC opportunities by the end of 2027. Cipher Digital...
NasdaqGS:VECO
NasdaqGS:VECOSemiconductor

Veeco Instruments (VECO) Margin Compression And Q1 Loss Test Bullish Growth Narratives

Veeco Instruments (VECO) opened 2026 with Q1 revenue of US$158.3 million, basic EPS of roughly a US$0.01 loss, and trailing 12‑month EPS of US$0.39 on US$655.3 million of revenue, setting up a quarter where profitability was in focus. The company has seen quarterly revenue move from US$167.3 million and basic EPS of US$0.21 in Q1 2025 to US$158.3 million and a small loss in Q1 2026, while trailing 12‑month EPS moved from US$1.31 on US$717.3 million of revenue at Q4 2024 to US$0.39 on US$655.3...
NYSE:AIR
NYSE:AIRAerospace & Defense

Has AAR (AIR) Risen Too Far After Recent Aerospace And Defense Sector Interest

If you are wondering whether AAR at US$118.71 is still reasonably priced after a strong run, this article walks through what the current share price might imply about value. The stock has recent returns of 12.3% over 7 days, 4.1% over 30 days, 40.6% year to date and 101.0% over the last year, which naturally raises questions about how much upside or risk is now priced in. Recent headlines have focused on AAR's role within the broader Aerospace & Defense sector and how investors are reacting...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks

FDA approves an expanded label for ASCENIV to include pediatric immunodeficiency patients aged two and older. The decision allows earlier intervention for immune compromised children and broadens ASCENIV’s eligible patient pool. The approval fulfills a key post marketing commitment for ADMA Biologics and may influence future commercial uptake. For ADMA Biologics (NasdaqGM:ADMA), this regulatory milestone arrives with the stock trading at $10.08 after a very large 5 year return and a 182.4%...
NasdaqGS:DDOG
NasdaqGS:DDOGSoftware

Assessing Datadog (DDOG) Valuation As FedRAMP High Certification And Earnings Anticipation Draw Focus

What is putting Datadog (DDOG) in focus now? Datadog (DDOG) is back on many watchlists after securing FedRAMP High certification and heading into a first quarter earnings report. Options markets expect that report could trigger a meaningful price move. See our latest analysis for Datadog. Datadog’s recent FedRAMP High certification and the upcoming earnings report arrive as the stock trades at US$143.71, with a 30-day share price return of 23.36% and a 1-year total shareholder return of...
NasdaqCM:AHG
NasdaqCM:AHGHealthcare

Is Akso Health Group's (AHG) Early BCI Bet Quietly Redefining Its Long-Term Innovation Narrative?

In April 2026, Akso Health Group announced it had begun a next-generation Brain-Computer Interface research and development program, building foundational infrastructure to pursue ultra-high-resolution neural sensing, real-time AI neural decoding, and advanced interface design, with related patent applications pending. The company emphasized that it has not yet started human clinical trials, made any regulatory submissions, or generated revenue from BCI activities, underscoring the...
NYSE:ONTO
NYSE:ONTOSemiconductor

Onto Innovation (ONTO) Margin Reset From 21.3% To 10.3% Tests Bullish Growth Narratives

Onto Innovation (ONTO) has opened 2026 with Q1 revenue of US$291.9 million and basic EPS of US$0.68, setting a clear benchmark for how the rest of the year may shape up. The company has seen quarterly revenue move between US$218.2 million and US$291.9 million over the last six reported periods, while basic EPS has ranged from US$0.21 to US$1.30. This gives investors a concrete sense of how top line and per share earnings have tracked through recent cycles. With trailing 12 month net profit...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Mercury Systems (MRCY) Q3 Loss Compression Challenges Longstanding Bearish Profitability Narratives

Mercury Systems (MRCY) has just posted its Q3 2026 numbers, with revenue of US$235.8 million, a basic EPS loss of US$0.05, and net income loss excluding extra items of US$2.9 million shaping the latest snapshot of performance. The company has seen quarterly revenue move from US$211.4 million in Q3 2025 to US$235.8 million in Q3 2026, while basic EPS has shifted from a loss of US$0.33 to a loss of US$0.05 over the same period. This leaves investors weighing top line scale against still...
NasdaqGS:EFSC
NasdaqGS:EFSCBanks

Does EFSC’s Share Buybacks And Higher Dividends Reshape The Bull Case For Enterprise Financial Services?

In April 2026, Enterprise Financial Services Corp reported first-quarter 2026 results with net income of US$49.4 million and diluted EPS of US$1.30, supported by higher net interest income, solid credit metrics, and a tax-equivalent net interest margin of 4.28%. The company also completed a multi-year repurchase of 1,368,517 shares and approved higher common and ongoing preferred dividends, underscoring an increased emphasis on returning capital to shareholders while maintaining a...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Perrigo (PRGO) Q1 Loss Of US$389.9 Million Tests Profit-Recovery Narratives

Perrigo (PRGO) opened Q1 2026 with revenue of US$969.2 million and a basic EPS loss of US$2.81, while net income excluding extra items came in at a loss of US$389.9 million. Over the past six reported quarters, revenue has ranged between US$969.2 million and US$1.14 billion and basic EPS has moved from a small profit of US$0.09 in Q3 2025 to a loss of US$10.20 in Q4 2025 and US$2.81 in the latest quarter, giving investors a wide view of how the income statement has changed across different...